İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2023 · article

Real-life experiences with galcanezumab and predictors for treatment response in Turkey

Dergi Springer Science and Business Media LLC ISSN kaydı başka bir dergiye işaret ediyor; ad YÖKSİS kaydından.
ISSN1471-2377
YÖKSİS OpenAlex Açık erişim · gold
Yıl2023
Atıf6OpenAlex
Yüzdelik%76,2
FWCI1,051,00 = dünya ortalaması
Scopus (SJR)Q2
WoS (JCR)Q3

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıSpringer Science and Business Media LLC
  • Katalog eşleşmesi (ISSN)BMC Neurology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

BACKGROUND: The complexity of clinical practice extends far beyond the controlled settings of trials, and there is a need for real-world studies aimed at identifying which patients will respond to anti-CGRP monoclonal antibodies in different countries. This study aimed to investigate the efficacy and safety of galcanezumab in treating migraine in a real-life setting in Turkey, as well as identify predictors of treatment response. METHODS: A total of 476 patients who diagnosed with migraine according to ICHD-3 criteria and treated with galcanezumab by headache specialists were voluntarily participated in this cross-sectional study. Galcanezumab is indicated for the prevention of migraine in adults who have at least 4 monthly migraine days in Turkey. All patients filled out a survey on Google Form that comprised 54 questions, addressing various aspects such as demographics, migraine characteristics, previous use of acute symptomatic medication, failures with preventive drug classes, comorbidities, most bothersome symptoms, as well as the interictal burden of migraine. RESULTS: Among the participants, 89.3% reported that galcanezumab treatment was beneficial for them. A decrease in the frequency (80.0%), severity (85.7%), and acute medication usage for migraine attacks (71.4%) was reported with galcanezumab treatment. An adverse effect related to galcanezumab was reported in 16.3% of cases, but no serious adverse reactions were observed. Remarkably, 14.3% of participants reported no longer experiencing any headaches, and 18.9% did not require any acute treatment while receiving galcanezumab treatment. A logistic regression model showed that male gender, lack of ictal nausea, and previous failure of more than 2 prophylactic agents may predict the non-responders. CONCLUSIONS: The first large series from Turkey showed that galcanezumab treatment is safe and effective in most of the patients diagnosed with migraine by headache experts in the real-life setting. Patients reported a significant decrease in both ictal and interictal burden of migraine and expressed satisfaction with this treatment.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

6atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 3 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2024 Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implicationsAtıf 24 · OpenAlex
  2. 2024 Are we closer to achieving precision medicine for migraine treatment? A narrative reviewAtıf 7 · OpenAlex
  3. 2024 Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraineAtıf 5 · OpenAlex

Yazarlar

17
  1. PINAR YALINAY DİKMEN 1
  2. Betül Baykan 2
  3. Derya Uludüz 3
  4. AYNUR ÖZGE 4
  5. ELİF ILGAZ ÇAĞLAYAN 5
  6. BURCU POLAT 6
  7. HAMDİ NECDET KARLI 7
  8. NERMİN TEPE 8
  9. NEŞE ÇELEBİSOY 9
  10. Hayal Ergin Toktaş 10
  11. Buket Niflioğlu 11
  12. RAHŞAN KARACI 12
  13. SAİME FÜSUN DOMAÇ 13
  14. Ezgi Uludüz 14
  15. TUBA ERDOĞAN SOYUKİBAR 15
  16. NEVRA ÖKSÜZ GÜRLEN MERSİN ÜNİVERSİTESİ 16
  17. Mustafa Ertaş 17